Verve Therapeutics

VERVE THERAPEUTICS INC

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.

Cathie Wood Ark Tesla

Equities

News

Markets

ETFs

ACHR

ARKK

AVAV

BLDE

NTLA

TDOC

TSLA

VERV

Cathie Wood&#39;s Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally

Cathie Wood

$BTC

ABSI

ARKW

COIN

ROKU

On Monday, Cathie Wood-led Ark Invest made some significant trades, with Coinbase Global Inc. (NASDAQ:COIN) taking the spotlight. This comes amidst a turbulent market scenario, particularly for cryptocurrencies.



The COIN Trade

Cathie Wood&#39;s Ark Invest Sells Coinbase Shares As Bitcoin Drops Below Key $62K Level

cathie_wood_bz_ark

$ETH

ARCT

ARKF

ARKQ

HOOD

MKFG

Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Video Communications Inc (NASDAQ:ZM).

Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M

Verve Therapeutics Inc

MGI MEDIA & GAMES INVEST by MGI MEDIA & GAMES INVEST SE

Verve Group SE

Press Releases

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

General

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

Health Care

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm

Earnings

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

Management

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

ABOS

CLYM

LENZ

SLDB

Absci

Abivax

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Altimmune

Astria Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Celcuity

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

Erasca

Heron Therapeutics

Keros Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Regenxbio

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sana Biotechnology

Stoke Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Tourmaline Bio

Upstream Bio

HC Wainwright & Co.

RBC Capital

Canaccord Genuity

Stifel

Cantor Fitzgerald

Comments

Verve Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga